Gene somatic mutations are commonly found in chordoma, in which TBXT, CDKN2A, and LYST accounting for a higher proportion.[7] TBXT is a diagnostic marker of chordoma and its single‐nucleotide polymorphism (rs2305089), germline duplication and somatic copy‐number gains confer major susceptibility to chordoma.[7, 8] Thus, targeting TBXT is a candidate option for chordoma treatment. The gene discussed is TBXT; the disease is chordoma.